Entera Bio (ENTX) EBT Margin (2019 - 2025)

Entera Bio (ENTX) has reported EBT Margin for 6 consecutive years, with 6235.71% the latest figure, recorded in Q1 2025.

• Quarterly EBT Margin changed N/A year-over-year to 6235.71% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 28383.33% (down 2293471.0% YoY) and the FY2025 annual result came in at 27235.71%, down 2197218.0% from the prior year.
• EBT Margin declined to 6235.71% in Q1 2025 per ENTX's latest filing, from 2858.54% in the prior quarter.
• Over the last five years, EBT Margin for ENTX reached as high as 1471.34% in Q1 2021 and fell as low as 35912.5% in Q3 2022.
• A 4-year average of 8329.29% and a median of 4923.46% in 2022 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2021 — EBT Margin soared 375480 bps — and 2022, when it slumped 3360750 bps.
• Year by year, EBT Margin stood at 2493.94% in 2021, then tumbled by 782 bps to 22007.14% in 2022, then soared by 87 bps to 2858.54% in 2024, then slumped by 118 bps to 6235.71% in 2025.
• According to Business Quant data, EBT Margin over the past three periods registered 6235.71%, 2858.54%, and 7192.86% for Q1 2025, Q4 2024, and Q3 2024 respectively.